This report provides an in-depth analysis of the market access climate in emerging pharmaceutical markets. Focusing in particular on the E7 countries (Brazil, Russia, India, China, Mexico, Indonesia, and Turkey), it charts recent developments, assesses their potential impact on market access, and pinpoints areas in which further change is anticipated.
Governments in emerging markets are under growing pressure to provide patients with access to innovative drugs, but pricing is the subject of increasing debate. After years of stalemate, innovative drugs have begun to reach public formularies as both parties appear ready to compromise.
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email email@example.com for further help or assistance.